Zacks Investment Research cut shares of Collegium Pharmaceutical (NASDAQ:COLL) from a hold rating to a sell rating in a research note issued to investors on Friday.
According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
COLL has been the subject of several other research reports. BidaskClub cut shares of Collegium Pharmaceutical from a sell rating to a strong sell rating in a research report on Tuesday, September 18th. Cantor Fitzgerald reiterated a buy rating and issued a $35.00 price objective on shares of Collegium Pharmaceutical in a report on Thursday. HC Wainwright reiterated a buy rating on shares of Collegium Pharmaceutical in a report on Monday, September 17th. Finally, Janney Montgomery Scott set a $27.00 price objective on shares of Collegium Pharmaceutical and gave the company a buy rating in a report on Monday, August 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $31.71.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.14). Collegium Pharmaceutical had a negative return on equity of 61.82% and a negative net margin of 39.10%. The firm had revenue of $70.20 million during the quarter, compared to the consensus estimate of $74.79 million. During the same quarter last year, the company posted ($0.45) EPS. Collegium Pharmaceutical’s revenue for the quarter was up 485.0% on a year-over-year basis. As a group, equities research analysts expect that Collegium Pharmaceutical will post -1.53 earnings per share for the current fiscal year.
In other news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $16.53, for a total value of $413,250.00. Following the completion of the transaction, the director now directly owns 361,000 shares in the company, valued at $5,967,330. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 25.76% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. Janus Henderson Group PLC boosted its holdings in Collegium Pharmaceutical by 8.1% during the third quarter. Janus Henderson Group PLC now owns 4,119,823 shares of the specialty pharmaceutical company’s stock worth $60,726,000 after buying an additional 309,477 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in Collegium Pharmaceutical by 9.9% during the second quarter. Macquarie Group Ltd. now owns 2,588,356 shares of the specialty pharmaceutical company’s stock worth $61,732,000 after buying an additional 233,598 shares in the last quarter. BlackRock Inc. boosted its holdings in Collegium Pharmaceutical by 7.0% during the third quarter. BlackRock Inc. now owns 2,409,573 shares of the specialty pharmaceutical company’s stock worth $35,517,000 after buying an additional 157,300 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Collegium Pharmaceutical by 54.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 649,624 shares of the specialty pharmaceutical company’s stock worth $9,575,000 after buying an additional 229,968 shares in the last quarter. Finally, Rice Hall James & Associates LLC boosted its holdings in Collegium Pharmaceutical by 29.7% during the third quarter. Rice Hall James & Associates LLC now owns 565,942 shares of the specialty pharmaceutical company’s stock worth $8,342,000 after buying an additional 129,432 shares in the last quarter. Hedge funds and other institutional investors own 94.41% of the company’s stock.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Recommended Story: How are institutional investors different from individual investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.